With the world fighting against the COVID-19 pandemic, scientists and researchers are trying their best to develop an effective vaccine, and the trials are fully on. From the safety measures to be taken to the final stage of clinical trials, they are giving their best to bring the situation under control. However, the question that still remains unanswered is that whether a vaccine is the only solution to put an end to COVID-19 and if it is how instantly it’s going to work in controlling the global epidemic.

Among 21,751 articles that have been published to date on Pubmed, a search engine used to retrieve peer-reviewed biomedical publication and life science literature, 1024 are related to vaccination. Google search results for COVID-19 displays multiple results, of which 32 million are related to vaccination.  The current scenario depicts the multiple trials that are in progress, with 159 candidate vaccines already under trial all around the world. The trends indicate how the vaccine is being looked upon as one of the best ways to treat coronavirus.

Of course, vaccination is a cost-effective way of preventing infectious diseases. However, it takes approximately 5-10 years for it to go through various clinical development stages to be approved and to be fit for use. And until the time the effective vaccines are well-deployed, the community already develops herd immunity, which protects it against the infection.

“We do need to realize that by the time the vaccine is available, perhaps the brunt of the pandemic would have diminished and a substantial proportion of the population would have developed herd immunity by either subclinical or clinical infection,” Indian scientists Dr. Ashok Datta, a Senior Emeritus Pediatrician at Appolo Hospitals Delhi, and Dr. Anupam Sibal, a Group Medical Director & Senior Consultant, Pediatric, Gastroenterology, and Hepatology in Appolo Hospitals, wrote in an article for The Quint.

Given the current scenario in the United States, the vaccine updates received from the Oxford and Moderna, an American biotech company, are highly awaited. In collaboration with the National Institute of Allergy and Infectious Disease, two Moderna vaccines are in the development process. The vaccine is a messenger RNA based solution using a two-dose schedule, and it is in phase II clinical trial at the moment.